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Abstract
Background: In case of suspicious lymph nodes on computed tomography (CT) or fluorodeoxyglucose
positron emission tomography (FDG-PET), advanced tumour size or central tumour location in patients with
suspected non-small cell lung cancer (NSCLC), Dutch and European guidelines recommend mediastinal
staging by endosonography (endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS)) with
sampling of mediastinal lymph nodes. If biopsy results from endosonography turn out negative, additional
surgical staging of the mediastinum by mediastinoscopy is advised to prevent unnecessary lung resection due
to false negative endosonography findings. We hypothesize that omitting mediastinoscopy after negative
endosonography in mediastinal staging of NSCLC does not result in an unacceptable percentage of
unforeseen N2 disease at surgical resection. In addition, omitting mediastinoscopy comprises no extra waiting
time until definite surgery, omits one extra general anaesthesia and hospital admission, and may be
associated with lower morbidity and comparable survival. Therefore, this strategy may reduce health care
costs and increase quality of life. The aim of this study is to compare the cost-effectiveness and cost-utility of
mediastinal staging strategies including and excluding mediastinoscopy.
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Methods/design: This study is a multicenter parallel randomized non-inferiority trial comparing two
diagnostic strategies (with or without mediastinoscopy) for mediastinal staging in 360 patients with suspected
resectable NSCLC. Patients are eligible for inclusion when they underwent systematic endosonography to
evaluate mediastinal lymph nodes including tissue sampling with negative endosonography results. Patients
will not be eligible for inclusion when PET/CT demonstrates ‘bulky N2-N3’ disease or the combination of a
highly suspicious as well as irresectable mediastinal lymph node. Primary outcome measure for non-inferiority
is the proportion of patients with unforeseen N2 disease at surgery. Secondary outcome measures are
hospitalization, morbidity, overall 2-year survival, quality of life, cost-effectiveness and cost-utility. Patients will
be followed up 2 years after start of treatment.
Discussion: Results of the MEDIASTrial will have immediate impact on national and international guidelines,
which are accessible to public, possibly reducing mediastinoscopy as a commonly performed invasive
procedure for NSCLC staging and diminishing variation in clinical practice.
Trial registration: The trial is registered at the Netherlands Trial Register on July 6th, 2017 (NTR 6528).
Keywords: Mediastinal staging, Mediastinoscopy, Non-small cell lung carcinoma, Endosonography, Thoracic
surgery
Background
Lung cancer is a common disease with over 12,000 new
Dutch cases annually and 1.8 million worldwide. In the
Netherlands 9175 new non-small cell lung cancer (NSCLC)
patients were diagnosed in 2017 [1, 2]. At diagnosis about
80% of patients already have distant or regional metastases,
whereas only 20% is eligible for surgical treatment with
curative intent. With (the suspicion of) potential curable
NSCLC, patients undergo computed tomography (CT) and
fluorodeoxyglucose positron emission tomography (FDG-
PET) in order to obtain information about locoregional and
distant disease. In case of absence of distant metastases but
presence of suspicious lymph nodes on PET/CT, Dutch
and European guidelines recommend mediastinal staging
by endobronchial (EBUS) and/or endoscopic esophageal
ultrasonography (EUS) with sampling of suspicious medias-
tinal lymph nodes [3]. In patients with non-FDG-avid
tumour, central tumour location or with peripheral tu-
mours > 3 cm, mediastinal staging is recommended as well.
In case of negative biopsy results from endosonography,
surgical staging of the mediastinum by mediastinoscopy is
advised to prevent possible unnecessary surgery due to false
negative endosonography findings. Generally only patients
without N2–3 metastases after mediastinoscopy are eligible
for intended curative anatomic resection. Patients with
pathologically proven N2–3 mediastinal lymph node me-
tastases are usually recommended to undergo first line che-
moradiation instead of surgery since no survival benefit has
been demonstrated by additional surgery [4]. When medi-
astinoscopy demonstrates potentially resectable N2 metas-
tases several treatment strategies can be followed: induction
chemotherapy followed by surgery, induction chemoradio-
therapy followed by surgery or definitive chemoradiother-
apy [5, 6].
In a randomized trial comparing endosonography
(EBUS and EUS) versus surgical staging, the sensitivity
for mediastinal nodal spread was 85% for endosonogra-
phy and 79% for mediastinoscopy with a total cohort
N2–3 prevalence of 46% [7]. Mediastinoscopy diagnosed
mediastinal lymph node metastases after negative endo-
sonography in 9.2% of patients, resulting in a combined
sensitivity of 94%, which is the rationale of recommend-
ing additional mediastinoscopy after negative endosono-
graphy. However, to detect one case of single level N2
disease, 11 patients need to undergo additional surgical
staging at the expense of morbidity, delay in diagnostic
work-up as well as financial costs. Several more non-
randomized comparative studies also demonstrated
higher sensitivity for endosonography than for mediasti-
noscopy [8–10]. These studies have raised questions on
how to identify false negative endosonography cases in
order to significantly reduce or even abandon additional
surgical staging.
Moreover, mediastinoscopy is associated with minor
(3.2%) and major (3.5%) complications, sporadic mortal-
ity (< 1%) and encompasses an additional invasive surgi-
cal procedure necessitating general anaesthesia and
delaying definite curative treatment [7, 11]. Therefore,
significantly reducing or even omitting the need for me-
diastinoscopy after negative endosonography may reduce
morbidity and mortality, as well as costs.
On the other hand, if all patients with negative endo-
sonography results would undergo an anatomic pulmon-
ary resection without additional mediastinoscopy, at
least 9.2% of patients would postoperatively turn out to
have unforeseen N2 disease. In the ASTER trial, all pa-
tients with negative endosonography results and subse-
quent positive mediastinoscopy had single lymph node
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station disease and one out of three had micrometas-
tases only [7]. Cerfolio et al. demonstrated good 5-yr
survival by surgical resection and adjuvant therapy in
single nodal station unforeseen N2 disease (40%) and
hereby reached comparable survival as in patients with
N1 disease [12]. Several others also showed favourable
5-yr survival rates in these patients [13, 14]. To
strengthen these figures, recent survival data from the
ASTER trial demonstrated equal 5-yr survival rates of
35% in both randomization groups, despite significantly
different detection rates of upfront N2 disease [15].
Therefore, surgical treatment of minimal unforeseen N2
disease instead of definite chemoradiation is increasingly
considered as treatment option as well [5, 6]. In
addition, the revised European Society of Thoracic Sur-
gery (ESTS) guideline of mediastinal staging states that
there is room for trials evaluating surgical treatment in-
stead of chemoradiation for minimal N2 disease [16].
The aim of this study is to compare the cost-
effectiveness and cost-utility of mediastinal staging strat-
egies including and excluding mediastinoscopy.
Methods/design
Hypothesis
Omitting mediastinoscopy after negative endosonogra-
phy in mediastinal staging of NSCLC does not result in
an unacceptable percentage of unforeseen N2 disease at
surgical resection. In addition, omitting mediastinoscopy
will shorten time until definitive surgery, will prevent
one general anaesthesia and hospital admission and will
be associated with lower morbidity and comparable sur-
vival. Therefore, this strategy may increase quality of life
and reduce health care costs.
Objective
The main objective of the proposed randomized trial is
to compare the cost-effectiveness and cost-utility of me-
diastinal staging strategies including and excluding me-
diastinoscopy, provided that non-inferiority of excluding
mediastinoscopy regarding unforeseen N2 disease can be
demonstrated.
Study design
This will be a multicentre parallel randomized trial com-
paring two diagnostic strategies (with or without medi-
astinoscopy) for mediastinal staging in patients with
suspected NSCLC, based on non-inferiority. The MED-
IASTrial flowchart is shown in Fig. 1.
Randomization
After written informed consent, provided at the out-
patient clinic, patient data are entered into a computer-
ized database (Research Manager) and with an
unchangeable computer generated number patients will
be randomized (1:1) to undergo either mediastinal sta-
ging with or without additional mediastinoscopy.
Randomization will be stratified by type of treatment
centre and, for its potential impact on cost-effectiveness
Fig. 1 Flowchart
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outcomes, by age below/above 66 years. Variable block
size randomization will be applied.
Blinding
Blinding of patients and physicians during staging and
treatment is unfeasible, since the two diagnostic strat-
egies and dependent treatments are highly different in
nature and in associated care.
Study population
Patients are eligible for inclusion in this trial when they
meet the following eligibility criteria:
(1) Diagnosed (with pathological proof by
bronchoscopic or transthoracic biopsy) or
suspected (based on CT and FDG-PET) with
NSCLC.
(2) CT and FDG-PET scan have excluded distant
metastasis (stage IV disease) or an irresectable
primary tumour (judged by thoracic surgeon, based
on imaging).
(3) One of the criteria defining the need for mediastinal
staging are met according to the European and
Dutch guidelines [16, 17]:
 PET/CT of the chest demonstrates CT-enlarged
(short axis > 1 cm) or FDG-PET avid hilar (cN1) or
mediastinal (cN2-N3) lymph nodes. PET is
considered positive if the standardized uptake value
(SUV) > 2.5, which is the ratio of the regional
radioactivity concentration divided by the injected
amount of radioactivity normalized to body weight
 CT demonstrates a centrally located primary
tumour, which is defined by visibility of the tumour
on video bronchoscopy within the main stem
bronchi; or tumour proximity to the mediastinum
< 0.5 cm on CT; or location of the tumour within
the inner 1/3 of the thorax. Whether the tumour
fulfils these criteria will be discussed by the local
multidisciplinary meetings
 FDG-PET demonstrates a FDG non avid primary
tumour.
 Peripheral lung tumours (outer two third of the
chest on CT) larger than 3 cm on CT
Inclusion criteria
(1) Patients underwent systematic EBUS, preferably
added by EUS, to evaluate mediastinal lymph nodes
including tissue sampling with negative biopsy
results. Adequate systematic EBUS / EUS is defined
as evaluation of at least lymph node stations 4 L, 7
and 4R by EBUS [18]. Preferably stations 4 L, 7 and
8 should be evaluated by subsequent EUS as well.
Lymph nodes in stations 4 L, 7 and 4R larger than
8 mm as well as all CT-enlarged (> 1 cm) and FDG-
avid (SUV > 2.5) mediastinal lymph nodes should be
sampled by at least 3 needle aspirations. In case of
FDG-avid nodes that are smaller than 8 mm and
have unsuspicious appearance on endosonography
punctures are not obligatory.
(2) Patients should be fit enough to undergo resection
of the primary tumour by either pneumonectomy,
(bi)lobectomy or segmentectomy, judged during the
local multidisciplinary meeting. Assessment of
fitness includes pulmonary function testing
(spirometry and diffusing capacity of the lung for
carbon monoxide), followed by cardiopulmonary
exercise testing (CPET) if deemed necessary by the
multidisciplinary board.
(3) Patients should be able to undergo cervical
mediastinoscopy (no current tracheostomy or
previous mediastinoscopy)
(4) Patient age of 18 years or older and able to give
informed consent and fill out questionnaires.
Exclusion criteria
(1) PET/CT demonstrates ‘bulky N2–3’ disease.
Definition of ‘bulky’ N2–3 disease is copied from
the definition given in the revised ESTS guideline:
mediastinal infiltration of more than one
mediastinal zone where the discrete lymph nodes
cannot be distinguished or measured during CT or
endosonography; or two or more lymph nodes with
a short axis of > 2.5 cm in more than one
mediastinal zone (according to the international
association for the study of lung cancer (IASLC)
node map) [16, 19].
(2) The combination of a highly suspicious as well as
irresectable mediastinal lymph node. High suspicion
of a lymph node is defined as FDG-PET SUV > 5
and at least 3 of the following ultrasonographic
malignant criteria: round shape, sharp borders,
hypo- echoic texture and short axis > 10 mm.
Whether a lymph node is irresectable is judged by
the surgeon, based on extracapsular growth or
growth into vital structures or due to unreachable
location (for example location in lymph node
station 4 L in case of a right sided operation).
(3) Non-correctable coagulopathy (international
normalized ratio > 1.7 or platelet count < 50 × 109/l).
(4) Insufficient comprehension of the Dutch language
to understand the trial information and to complete
the questionnaires during follow-up period.
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Participating centres
Twenty Dutch hospitals and one Belgian hospital partici-
pate in the MEDIASTrial study group, including seven
academic and fourteen non-academic centres, and will
enroll patients.
Intervention
Patients will undergo immediate anatomic resection of
the primary tumour by either pneumonectomy, (bi)lob-
ectomy or segmentectomy according to patient and
tumour characteristics as discussed by the local multi-
disciplinary lung meeting in the participating centre. If
possible, patients are treated by video-assisted thoraco-
scopy (VATS) or robotic-assisted thoracic surgery
(RATS). During the surgical procedure, at least a lobe-
specific mediastinal lymph node dissection will be done
according to European guidelines [3, 20].
Usual care (comparison)
According to current national and international
guidelines, patients will first undergo cervical medias-
tinoscopy. For this trial, only videomediastinoscopy
will be used. This procedure will be done under gen-
eral anaesthesia, and at least lymph node stations 2R,
4R, 4 L, and 7 should be sampled for right-sided tu-
mours, whereas at least station 4 L, 4R and 7 should
be sampled for left-sided tumours. Station 2 L will
only be removed when visualized or in case of suspi-
cion based on PET/CT [3, 16].
When histopathological examination of the resected
lymph nodes does not demonstrate metastases, patients
will undergo additional anatomic lung resection and at
least, a lobe-specific lymph node dissection as described
under ‘intervention’, which will serve as reference stand-
ard in both randomization groups.
When histopathology after mediastinoscopy demon-
strates N2–3 metastases, patients are generally recom-
mended to undergo definite chemoradiation. When
mediastinoscopy demonstrates potentially resectable N2
metastases several treatment strategies can be followed:
surgery and adjuvant chemotherapy, induction chemo-
therapy followed by surgery, induction chemoradiother-
apy followed by surgery or definitive chemoradiotherapy
[5, 6]. Discussion within the local multidisciplinary
meeting will decide exact treatment in these cases. Dif-
ferences in treatment between participating centres will
be adjusted by stratification per setting (academic, non-
academic). These patients will be followed according to
the routine follow-up scheme of this study.
Informed consent procedure
Consecutive patients will be checked for eligibility dur-
ing the multidisciplinary meetings in the participating
centres by the involved physicians (surgeon,
pulmonologist, radiation oncologist, radiologist, nuclear
medicine physician and pathologist). All patients fulfill-
ing the inclusion criteria will subsequently be informed
about the trial by their local pulmonologist or surgeon
at the next outpatient clinic visit (depending on local lo-
gistics). The MEDIASTrial informed consent form is at-
tached as Additional file 1. After informed consent is
given, randomization will take place by a computerized
randomization program, using Research Manager Soft-
ware and patients will be further staged and treated ac-
cording to the study protocol. Patients unable or
refusing to provide informed consent will be treated ac-
cording to current clinical guidelines, which is additional
surgical staging by mediastinoscopy.
Quality assurance
All participating centres should adhere to the European
Association of Nuclear Medicine procedure guidelines of
FDG-PET/CT for tumour imaging to guarantee high
quality of performing, interpreting and reporting FDG-
PET/CT-scan [21].
To assure high quality of endosonography, endosco-
pists have been trained in EBUS and EUS during their
training as pulmonologist. Additionally, endoscopists
participating in this study have performed a specific
endosonography lung cancer staging training module.
Also they have passed an EBUS skill and assessment tool
(EBUSAT) evaluating structural EBUS anatomy and
standardised mediastinal nodal sampling. The EBUSAT
has demonstrated reliable and valid assessment of com-
petence [18]. On individual basis, both EBUS simulator
training and clinical EBUS-EUS training will be offered
if necessary.
To assure high quality of mediastinoscopy and lymph-
adenectomy, surgical protocols and demands have been
written and will be monitored during the trial.
Outcome parameters
The following baseline characteristics will be collected;
gender, age at time of randomization, height, weight,
location of the primary tumour, World Health
Organization (WHO) performance state, American Soci-
ety of Anaesthesiologists (ASA) classification and
Tumour, Node, Metastases (TNM) classification (eight
edition). Schedule of events is shown in Table 1. To per-
form the cost-effectiveness and cost-utility analysis, the
following primary and secondary outcome measures are
chosen:
Primary outcome measure (for non-inferiority)
(1) As the goal of accurate mediastinal staging is the
prevention of performing lung surgery in patients
with N2 disease (e.g. unforeseen N2), the
Bousema et al. BMC Surgery  (2018) 18:27 Page 5 of 11
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proportion of patients with unforeseen N2 disease
after final lung resection and mediastinal
lymphadenectomy is considered as primary
outcome measure for the non-inferiority design of
this trial.
Secondary outcome measures
(a) The total number of days of hospital care, defined
as the total number of days in hospital after
randomization during a follow up period of 2 years.
Every day in hospital (including outpatient clinic
visits and day care treatments) related to NSCLC
diagnosis, treatment or follow-up will be counted.
(b) Costs of mediastinal staging strategies (including or
excluding surgical mediastinal staging) from a
societal perspective, based on primary data (see also
economic evaluation).
(c) Morbidity: the combination of major morbidity and
30-day mortality is chosen as composite outcome
measure. Major morbidity is defined as the
proportion of patients having morbidity of grade
III-IV (Clavien-Dindo classification) or recurrent
laryngeal nerve injury, which is a specific serious
adverse event associated with mediastinoscopy [22].
(d) Overall 2-year survival, defined as the proportion of
patients alive at 2 years follow-up, and 2-year
disease-free survival, defined as the proportion of
patients alive without evidence of relapse of disease
at 2 years follow-up. Follow-up is done by
pulmonologists at 3 monthly intervals during the
first year and 6 monthly intervals during the second
year. Hereafter, yearly follow-up will be done until
5 years after treatment. This follow-up scheme is in
concordance with the Dutch guideline of NSCLC.
Finally, 5-year overall and disease-free survival will
be measured after 5 years of follow-up.
(e) Generic and disease-specific health related quality
of life will be measured at baseline, 1 week after me-
diastinoscopy (only randomization group including
mediastinoscopy), 2 weeks after start treatment (e.g.
anatomic resection or chemo- and/or radiotherapy),
at 4 weeks, at 3 months, at 6 months, at 1 year and
at 2 year follow-up by the EQ-5D-5 L, EORTC
QLQ-C30 and QLQ-LC13 questionnaires.
Sample size calculation
In the ASTER trial, surgical staging with mediastinos-
copy had a sensitivity of 79% for detecting N2 disease vs.
94% for the combined use of endosonography and medi-
astinoscopy in a population with 75% PET/CT N2–3
disease positives [7]. Negative histology after staging was
followed by surgical mediastinal lymphadenectomy,
which provided the best possible reference standard.
The difference in sensitivities between the two staging
strategies in this trial led to unforeseen N2 rates of 14.
3% after surgical staging versus 6.9% after endosonogra-
phy ánd mediastinoscopy. Despite this difference in
diagnostic staging, 5-year survival rates were completely
equal (35% vs. 35%) [15]. Therefore, for our trial we as-
sume that the proportion of unforeseen N2 after omit-
ting mediastinoscopy (experimental arm in our trial)
may not exceed 14.3% as upper limit of its 95%-confi-
dence interval (non-inferiority) in order to have no nega-
tive impact on survival.
We conducted a systematic review about mediastinal
staging (unpublished data). Herein we found a propor-
tion of unforeseen N2 of 6.3% after endosonography
combined with mediastinoscopy (control group). We
found 6.8% unforeseen N2 nodes in patients staged with
endosonography alone, without mediastinoscopy. With
these results, we calculated to include 171 patients in
each randomization group (power 80%; alpha error
0.025). Based on an assumed 5% drop-out rate of pa-
tients after randomization, we aim to include a total
of 360 patients.
Ethics
This study will be performed in accordance with the
declaration of Helsinki, 64th WMA General Assembly,
Fortaleza, Brazil, October 2013 and in accordance with
the Medical Research Involving Human Subjects Act
(WMO, the Netherlands). The medical ethical commit-
tee of the Maxima Medical Center has approved the
study protocol (Medical Ethical Committee (MEC)
number W17.063). Important protocol modifications
will be communicated as soon as possible with the
local investigators and the Dutch Trialregister. Prior
to randomization, written informed consent will be
obtained from all patients.
Data safety
After written informed consent, patients will be assigned
a study number and clinical data will be registered
pseudonymous via Research Manager software. Research
Manager software is certified by the ‘Information Secur-
ity Management System 27001’. The key to the code is
safeguarded by the local principal investigator. Quality
of Life and Health Economics questionnaires will be co-
ordinated by the Netherlands Comprehensive Cancer
Organisation (IKNL), having extensive experience in ac-
quiring information on quality of life in cancer patients
in general. The gathered data will be collected in the
PROFILES registry by IKNL. The PROFILES registry re-
cently obtained the ‘Data Seal of Approval’.
Monitoring will be done by IKNL according to the
MEDIASTrial monitoring plan.
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All centers will be visited 3 months after inclusion of
the third patient. In case centers have high or low inclu-
sion rate or queries in datamanagment, additional moni-
tor visits will be done. Monitoring will take place with
specific attention to informed consent, data monitoring
and completeness of case record form.
Local data management will be done by IKNL, hav-
ing extensive experience with management of local
data collection. Collection, storage and analysis of
data will be done according to the MEDIASTrial data
management plan.
No data safety monitoring board will be established,
since this is a diagnostic trial of usual care evaluating
diagnostic strategies with an expected low complica-
tion rate.
Research data can be presented or published in agree-
ment with the principal investigator (FvdB) only. No re-
search data that can be traced to individual persons will
be presented or published. The research data will be re-
ported following the CONSORT guidelines.
Patient safety
The sponsor/coordinating investigator has an insurance
which is in accordance with the legal requirements in
the Netherlands (article 7 WMO). This insurance pro-
vides cover for damage to research subjects through in-
jury or death caused by the study. The insurance applies
to the damage that becomes apparent during the study
or within 4 years after the end of the study.
The sponsor/coordinating investigator will report the
concerning SAEs through the web portal ToetsingOnline
to the accredited METC that approved the protocol,
within 7 days of first knowledge for SAEs that result in
death or are life threatening followed by a period of
maximum of 8 days to complete the initial preliminary
report. All other SAEs will be reported within a period
of maximum 15 days after the sponsor/coordinating in-
vestigator has first knowledge of the SAEs.
In case subjects withdraw from study participation,
these patients will undergo treatment and follow-up
according to local treatment and follow-up protocols.
These individuals will be asked for permission to just
register their information on actual treatment and
regular follow-up, in order to report outcome of with-
drawn cases.
Data-analysis
The number of patients with pathologically proven N2
disease after final lung resection and lobe specific medi-
astinal lymphadenectomy divided by the total number of
patients who underwent lung resection with lobe specific
mediastinal lymphadenectomy is considered the propor-
tion of patients with unforeseen N2 (primary outcome
measure). These proportions will be compared between
the two randomization groups by the Chi square test,
based on intention to treat (ITT). Considering that a
non-inferiority hypothesis is tested a per protocol ana-
lysis (PP) will also be performed. Both, the ITT and the
PP analyses should indicate non-inferiority before the
diagnostic strategy without mediastinoscopy will be
assessed as non-inferior to the strategy with mediasti-
noscopy. Incongruent results from the ITT and PP ana-
lyses will be discussed. No interim analysis is planned.
The total number of days of hospital care will be
counted after randomization during a follow up period
of 2 years. The mean (or median) number of days plus
standard deviation (or interquartile range) will be com-
pared between groups by the Student’s t-test or Mann
Whitney U test depending on the distribution (normally
of skewed) of data. The number of patients with either
major morbidity or death within 30 days from definite
surgery divided by the total number of randomized pa-
tients is considered as the proportion of patients with ei-
ther major morbidity or 30-day mortality (composite
outcome measure). These proportions will be compared
between the two randomization groups by Chi-square
testing. The number of patients alive and the number of
patients alive without evidence of relapse of disease after
2 years follow-up divided by the total number of ran-
domized patients are considered as overall and disease-
free 2 year survival rates. The log rank test will be used
to compare the study arms, based on intention to treat.
Generic and disease-specific health-related quality of life
will be measured by EQ-5D-5 L, EORTC QLQ-C30 and
QLQ-LC13 questionnaires and provide continuous vari-
ables that will be compared between the randomization
groups by generalized linear mixed modelling. All ana-
lyses of secondary outcomes will be carried out on an
intention-to-treat basis.
Economic evaluation
The economic evaluation of both mediastinal staging
strategies will be performed as a cost-effectiveness
analysis as well as a cost-utility analysis from a societal
perspective. The primary outcomes for the cost-
effectiveness and cost-utility analyses are the costs per
patient without unforeseen N2 and the costs per QALY.
The costs per patient free of major complications/death
and the costs per patient alive after 2 years follow-up
will be considered as secondary outcome measures.
The cost-analysis will include health care costs, out-of-
pocket expenses and costs of production loss. The direct
medical costs will include the costs of all diagnostic pro-
cedures, therapeutic (repeat) interventions, medication,
admissions, day care treatments, specialist consultations,
and out-of-hospital care (like general physician, physio-
therapy) during follow-up. Out-of-pocket expenses will
include the costs of health-related travel, over-the-
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counter medication etc. Volume data will be gathered
with clinical report forms, available hospital information
systems, and the iMTA Medical Consumption Question-
naire (iMCQ) and iMTA Productivity Cost Question-
naire (iPCQ) adjusted to the study setting. The Dutch
costing guideline for health care research will be used to
determine the relevant unit costs. In case of the medias-
tinal staging strategy however, micro-costing (general
anaesthesia, surgical equipment, procedure duration, in-
volved personnel, overhead) in participating centres will
be done to estimate real unit costs. The friction costs
method will be applied to derive the costs of lost prod-
uctivity. After price-indexing all costs will be expressed
in 2018 Euros.
Incremental cost-effectiveness ratios will be calculated
with uncertainty margins based on non-parametric
bias-corrected and accelerated bootstrapping. Cost-
effectiveness acceptability curves will be drawn to
show the probability of a strategy being cost-effective
at various levels of willingness-to-pay per QALY up
to 100,000 euro. In case both mediastinal staging
strategies turn out clinically equivalent, the study will
be performed as a cost-minimization analysis.
Discussion
The MEDIASTrial will study whether mediastinoscopy
can be omitted after negative endosonography in medi-
astinal staging in patients with NSCLC. Since debate ex-
ists on the additional value of mediastinoscopy, this trial
will provide definite evidence on this topic [23–27]. The
current literature suggests that diagnostic strategies with
or without mediastinoscopy may be equivalent concern-
ing efficacy and that abandoning mediastinoscopy ap-
pears favourable concerning morbidity and speed of
diagnostic process. As a result, variety in daily practice
already exists in the extent of use of mediastinoscopy
throughout and within countries [7, 28, 29]. A formal
comparison of cost-effectiveness and cost-utility has
however never been performed and no ongoing studies
comparing these two strategies have been registered in
trial registers so far. Results of such a trial will have im-
mediate impact on national and international guidelines,
which are accessible to public, possibly abandoning me-
diastinoscopy as a commonly performed invasive pro-
cedure and diminishing variation in clinical practice.
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